Heinemann Lutz, Franc Sylvia, Phillip Moshe, Battelino Tadej, Ampudia-Blasco Francisco Javier, Bolinder Jan, Diem Peter, Pickup John, Hans Devries J
Science & Co., Düorf, Germany.
J Diabetes Sci Technol. 2012 Nov 1;6(6):1498-502. doi: 10.1177/193229681200600631.
Different systems for continuous glucose monitoring (CGM) are available on the European market. There is no unlimited reimbursement for CGM use in any European country, but in some countries, reimbursement exists for certain clinical indications. The aim of this commentary is to describe the different reimbursement situations across Europe for this innovative but costly technology, as a prelude to establishing more uniform use. From the perspective of many scientists and clinicians, a number of randomized controlled trials have demonstrated the efficacy of real-time CGM versus self-monitoring of blood glucose, at least for hemoglobin A1c reduction. Nevertheless, according to many health care professionals and potential CGM users, national health services and health insurance organizations are reluctant to reimburse CGM. Imminent technological and manufacturing developments are expected to reduce the day-to-day costs of CGM.
欧洲市场上有不同的连续血糖监测（CGM）系统。在任何欧洲国家，CGM的使用都没有无限制的报销，但在一些国家，某些临床适应症的使用是可以报销的。本评论的目的是描述这种创新但昂贵的技术在欧洲各地不同的报销情况，作为建立更统一使用的前奏。从许多科学家和临床医生的角度来看，一些随机对照试验已经证明了实时CGM相对于自我血糖监测的有效性，至少在降低糖化血红蛋白方面是如此。然而，据许多医疗保健专业人员和潜在的CGM用户称，国家医疗服务机构和健康保险组织不愿为CGM报销。预计即将到来的技术和制造发展将降低CGM的日常成本。
